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Abstract
The recent surge in opioid-related deaths has brought poor pain management 
practices to the forefront of our nation’s collective consciousness. However, improv-
ing treatments for chronic pain, substance use disorders (SUD), and comorbid 
expression of both requires a better understanding of the pathophysiology involved 
in their development. In this chapter, the authors present the argument that chronic 
pain and SUD can be conceptualized similarly from a biopsychosocial perspec-
tive to inform a better approach to treatment. The authors describe the common 
neurobehavioral mechanisms of SUD and chronic pain, then discuss the efficacy of 
several psychotherapeutic methods employed to combat chronic pain, addiction, 
and related disorders. Such methods may contribute to positive health outcomes in 
managing chronic pain and curbing drug addiction by reducing the role of opioid 
analgesics for long-term pain management.
Keywords: addiction, substance use disorders, chronic pain, opioids, psychotherapy, 
cognitive behavioral therapy, mindfulness-based stress reduction, solution-focused 
brief psychotherapy, motivational interviewing
1. Introduction
Over the past two decades, the rate of prescription drug misuse has been rapidly 
increasing worldwide, leading to a growing number of emergency department 
visits, hospitalizations, and overdose deaths. The National Safety Council reported 
that in 2017, it was more common to die of opioid overdose than in a car crash, and 
by 2018, drug overdose became the number 1 cause of unintentional death in the 
United States. The coronavirus pandemic has only exacerbated this situation [1]. 
Opioid analgesics have become the most commonly prescribed class of drugs in the 
United States [2] in part because approximately 100 million American adults suffer 
from chronic pain, more than those affected by heart disease, diabetes, and cancer 
combined [3]. The other major piece of this puzzle is that prescription opioids were 
misrepresented by pharmaceutical manufacturers as non-addictive, which led to 
widespread over-prescription of opioids for long-term chronic pain management. 
Although the addictive potential of oxycodone was recognized very early [4], very 
few studies have been conducted on this or other opioid painkillers. Recently, the 
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growing recognition that prescription opioids can be addictive has also led some 
doctors to over-correct the problem by not prescribing sufficient opioids to manage 
pain when it is appropriate, leaving patients to seek illegal sources or substances 
(e.g. heroin) to manage pain and physical withdrawal symptoms. These oppos-
ing but equally ill-informed prescription practices have culminated into a single 
outcome: an epidemic of opioid addiction and death in the United States.
From many different perspectives, chronic pain and substance use disorders 
(SUD) share a plethora of similarities and thus it is not surprising that they 
frequently occur in tandem, with either one preceding the other. Overall, the 
prevalence of chronic pain in individuals with SUD is estimated to be 27–87%, with 
individuals suffering from chronic pain 2-3X more likely to experience a SUD, and 
individuals that have a SUD 1.5 times more likely to experience chronic pain [5]. 
In people receiving an opioid prescription for long-term chronic pain treatment, 
21–29% misuse the opioid medication and 8–12% develop an opioid use disorder 
(OUD) [6, 7], though some estimates are as high as 43%, with elevated risk for 
other substance-related disorders as well [5]. Some hypothesize that individuals 
self-medicate with drugs to manage the psychological aspects of pain [8, 9], while 
others suggest pre-existing physiological and psychological characteristics associ-
ated with OUD/SUD can be stimulated by a chronic pain condition [9, 10]. These 
hypotheses are not mutually exclusive, and draw attention to the fact that the 
relationship between chronic pain and SUD is difficult to disentangle, making it 
complicated to establish effective treatments.
As with many societal weaknesses exposed by the pandemic, SUD, particularly 
OUD, are flourishing and overdose deaths continue to rise [1]. This does not appear 
to be due solely to the disease itself, but rather the significant increase in life stress 
(e.g. job loss, social isolation, etc.) combined with lack of access to proper mental 
and physical health care. This illustrates well the central hypothesis we aim to 
present: that a biopsychosocial perspective of addiction and chronic pain, which 
incorporates factors from the societal to molecular levels, allows for a more thor-
ough understanding of these disorders. We suggest that incorporating alternative 
therapeutic methods and reducing the role of opioid analgesics for long-term pain 
management may contribute to positive health outcomes in managing chronic pain, 
addiction, and comorbid expression of both.
2. Biopsychosocial approach to understanding health and disease
As the name suggests, the biopsychosocial (BPS) model proposes that health-
care professionals use biological, psychological, behavioral, and social lenses to 
understand health and disease. Psychiatrist George Engel has been credited with 
the formulation, and call for action, that propelled the understanding of disease 
and illness past that of basic Renaissance philosophy and into an understanding not 
solely based in biological factors [11]. Engel introduced the BPS model as a contrast 
to the biomedical model of health and disease, which had long reigned supreme 
(and still predominates clinical practice in many fields). His model also contrasts 
with a purely environmental/ecological model, which holds a more holistic view 
of health, but may neglect the importance of biological influences. The BPS model 
incorporates the best of both worlds, recognizing that both nature and nurture are 
vitally important to health and disease. This new ideal formed the foundation for 
behavioral and psychological conceptualizations of health and medicine [12].
The BPS model has now become the leading one in conceptualizing many forms of 
illness, including chronic pain, although it continues to be underutilized in practice, 
particularly in acute medical and surgical fields of study that prioritize biomedical 
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views of disease and illness [13]. A large part of the problem in translating concept 
to practice is that the BPS model has minimal influence over provisional healthcare 
funding [13]. Critics of the BPS model claim that the diagnostic front would be 
marginalized by utilizing a threefold framework (although this had already been 
addressed by functional and practical analysis) [14, 15]. Biomedical model propo-
nents suggest that the BPS model may promote a lack of focus, or that practitioners 
may misjudge other significant factors related to treatment, and therefore cause unin-
tended harm to patients due to the complexity of the biopsychosocial approach and 
the negligence that may occur [14]. However, it is important to consider that harm can 
be associated with any models or frameworks, and that harm primarily results from 
misuse of models and failures to recognize limitations of those models [13].
The opioid epidemic is a profound and tragic illustration of the problems associated 
with the persistence of the biomedical model in many fields and countries (includ-
ing the U.S.). This model has seen healthcare costs soar, while patient outcomes have 
fallen. A major cause of these failings is the lack of consideration of psychosocial 
factors in patients’ lives, which can contribute greatly to overall health. Two recent 
Nature articles have drawn attention to the importance of social context - and the 
shortcomings of a biomedical-only approach - in relation to substance use. Hart 
(2017) argues that even conceptualizing addiction as a disease or disorder is not only 
inaccurate, but harmful, contributing to social injustice in the form of racism and 
socioeconomic marginalization [16]. He further takes issue with the exaggerated value 
placed upon neuroscientific evidence. Relatedly, Heilig et al. (2016) attributes the rela-
tive lack of addiction treatment advancements to the glaring omission of social context 
in neuroscience, and calls on the field to elucidate the impacts of social exclusion and 
marginalization on the development of drug-seeking and consumption [17]. Although 
these articles focus on addiction, the principles apply to chronic pain as well.
While solving the socioeconomic disparities that contribute to illness will be 
a formidable task that lies outside the scope of the current chapter, the authors 
argue that a biopsychosocial approach to addiction and chronic pain is superior to 
a strictly biomedical one, and that it has the potential to counteract the problems 
of a biomedical-only view. As noted above, the biomedical paradigm is struggling 
to confront rising healthcare costs and poor, patient-reported outcomes [13]. The 
BPS model, prided on person-centered care, can alleviate this financial and diag-
nostic burden, particularly as it relates to chronic pain, mental illness, and other 
functional disorders [13, 18]. The BPS model has the ability to yield more positive 
patient-reported outcomes of treatment, especially within the context of cognitive 
behavioral therapy, due to the person-centered approach and use of goal-setting, 
which has recognized utility in treating both chronic pain and SUD [19–21]. Family 
involvement in treatment can heavily reduce stigma related to SUD and chronic 
pain, and this social engagement is correlated with lasting, positive treatment 
outcomes [22]. If this model becomes more ingrained within the cultural sphere of 
Western clinical medicine and the general populace, it is predicted to drastically 
reduce societal stigma related to both chronic pain and SUD, thus altering perceived 
treatment outcomes and making non-pharmacological treatment more acceptable 
and accessible to those suffering [23]. Considerations of the social aspects of the 
BPS model would greatly advance future research, particularly that relating to 
psychological and behavioral functioning.
3. Neurobiological overlap between addiction and chronic pain
Epidemiological and functional imaging studies suggest a bidirectional relation-
ship between chronic pain and many psychiatric disorders, including SUD, and that 
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significant neurological overlap exists between them [5, 24, 25]. As described below, 
these similarities in affect, cognition, and behavior between addiction and chronic 
pain are reflected by similar changes in neural circuitry. These conditions also share 
many genetic and epigenetic mechanisms, but a detailed discussion is outside the 
focus of this chapter.
3.1 Neurobiology of substance use disorders
SUD are undeniably biopsychosocial in nature and expression, with hallmark 
features of impaired daily functioning in cognitive, physiological, psychological, 
and social domains as a result of substance use and continued use despite these 
negative consequences. Diagnostic criteria for SUD include impaired cognitive 
and behavioral control over drug use, social impairment, such as job or relation-
ship loss, use of drugs in risky or inappropriate situations that pose physical or 
psychological harm, and pharmacological criteria such as tolerance and withdrawal 
[26]. Neuroscientists conceptualize the addicted brain in a framework that encom-
passes key elements of two theories of motivated behavior: incentive-sensitization 
theory, wherein the motivation to consume drugs is said to result from conditioned 
reinforcement and over-attribution of salience to drugs and drug cues [27], and 
opponent-processes theory [28], which holds that the motivation to consume 
drugs is initially driven by positive reinforcement (addition of pleasurable feelings 
or euphoria, e.g. reward/process A), but repeated drug use is driven by negative 
reinforcement (subtraction of aversive feelings or state associated with drug depri-
vation, e.g. antireward/process B). These theories have given rise to the concept 
of the addiction cycle, which is supported by abundant neuroscientific evidence 
(reviewed extensively in [29] and summarized below).
The addiction cycle is composed of three stages, each underlain by neuroplastic 
changes in the function of discrete brain circuits resulting from chronic drug 
exposure, with variability modulated by an individual’s genetics, life experi-
ences, and their drug(s) of choice. The binge/intoxication stage is characterized 
by drug-induced positive reinforcement and loss of control over the amount and 
duration of drug-taking. The main circuit involved in acute drug reinforcement is 
the dopaminergic projection from the ventral tegmental area (VTA) to the nucleus 
accumbens (NAc), supported by the central nucleus of the amygdala (CeA) and 
ventral pallidum (VP), while compulsivity in drug-taking involves the caudate/
putamen (CPu). Repeated drug use reduces baseline activity of these circuits, 
partly setting the stage for withdrawal/negative affect to drive drug-taking. The 
withdrawal/negative affect stage is marked by negative reinforcement (removal 
of unpleasant stimulus or emotional state) driven by the recruitment of the 
hypothalamic–pituitary–adrenal (HPA) stress axis and circuitry connecting the 
basolateral amygdala (BLA) and hippocampus to the extended amygdala, CeA, 
basal nucleus of the stria terminalis (BNST), and a subregion of the NAc shell, 
which in turn project to the VP and lateral hypothalamus (LH). Acute withdrawal 
from several drugs, including opioids, involves hyperactive corticotropin-releasing 
factor (CRF) and norepinephrine (NE) neurotransmitter systems, the endogenous 
antireward opioid dynorphin, substance P, neuropeptide Y, vasopressin, and 
nociceptin. The preoccupation/anticipation stage is marked by drug craving, key 
to the relapsing nature of the addiction cycle. The impetus of relapse determines 
the neurocircuitry involved, with drug-induced relapse regulated by glutamatergic 
projections from the medial PFC (mPFC) to the NAc and VP, cue-induced relapse 
regulated by BLA-PFC-NAc glutamate signaling and VTA-PFC dopamine signal-
ing, and stress-induced relapse activating the extended amygdalar CRF and NE 
systems. Compromised cognition, memory, and inhibitory control involve the 
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hippocampus, mPFC and orbitofrontal cortex (OFC; [29]. As the authors discuss 
below, many of the structures, circuits, and neurochemical mediators that drive 
SUD are also involved in chronic pain.
3.2 Neurobiology of chronic pain
Nociception is a physiological response to a noxious stimulus wherein normally 
silent sensory neurons called nociceptors deliver information to the brain to elicit 
protective actions [30]. When stimulated, nociceptors transduce signals along 
spinal cord primary afferent Aδ and C fibers and converge at the dorsal horn, where 
afferent neurons in laminae I and V provide input to the brain [31]. Pain results 
from the activation of a distributed group of brain structures within the brainstem 
reticular formation and the limbic system, collectively referred to as the pain neuro-
matrix [32], a three-tiered hierarchy of experiential pain processing [33]. First order 
processing occurs when the spinothalamic and spinoreticulothalamic tracts carry 
signals from the dorsal horn into the brainstem and posterior thalamus (pTHAL), 
which encodes localization of pain and identification of specialized pain character-
istics [31, 33]. The second tier involves perceptive and attentional internalization of 
pain, including cognitive structuring and modulation, attenuation, and proposition 
of somatic reactions to the painful stimuli, and is regulated by the posterior parietal 
cortex (pPAR), anterior cingulate cortex (ACC), PFC, and insula [33]. The third 
tier is characterized by emotional reappraisal of the nociceptive stimuli, in which 
emotional context is applied to the experience to modulate its psychological and 
social consequences. The brain regions associated with this tier are the pPAR, OFC, 
and anterolateral PFC [33]. These cortical structures are responsible for determin-
ing the behavioral response to nociceptive stimulation [31, 34].
Chronic pain is defined as persisting past the normal time of healing, gener-
ally for six months or more [35]. Unlike acute pain, which is protective in nature, 
chronic pain has negative effects on psychological and social well-being. As with 
SUD, chronic pain is the result of the plastic nature of molecules and circuits within 
the nervous system [31]. When activated persistently, the pain neuromatrix and 
other regions of the brain and spinal cord involved in nociceptive and cognitive-
evaluative processing undergo neuroplastic changes that amplify activity, called 
central sensitization [36–38]. These changes result in exaggerated responses to 
noxious stimuli (hyperalgesia) and pain responses being triggered by normally 
innocuous stimuli (allodynia). The transition from acute to chronic pain is under-
lain by greater engagement of emotional and motivational circuitry [39], paralleling 
the progression through the addiction cycle.
Not surprisingly, research suggests that there is significant overlap in the neuro-
logical mechanisms involved in chronic pain with those involved in drug addiction 
[29, 40, 41]. Neuroplastic changes in corticolimbic structures comparable to those 
seen in SUD also contribute to pain chronification [42]. Specifically, chronic pain, 
like SUD, involves neuroadaptations that dampen reward, recruit stress-related 
circuitry, and promote aberrant learning that converge to negatively affect physiol-
ogy and behavior [39, 42–45]. Chronic pain can disrupt the reward/antireward 
balance through persistent sensitization of nociceptive circuitry within the NAc, 
and attenuation of behavioral inhibitory signaling from the habenula [46, 47] 
to produce an overall shift in reward level or hedonic tone [48]. NAc functional 
connectivity changes have also been associated with risk-taking behavior in chronic 
pain patients, with high gain sensitivity in sufferers of chronic back pain correlated 
to greater connectivity between NAc and subcortical areas, compared to controls 
with strong NAc-frontal cortex connectivity [49]. These changes can promote 
the use of alcohol and drugs, particularly opioids, for negative reinforcement 
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(alleviating physical and psychological pain) and ultimately predispose chronic 
pain sufferers to develop drug addiction [39, 43].
As discussed above, both repeated exposure to addictive drugs and chronic pain 
lead to changes in brain function that promote continued drug use. Conversely, 
recurring drug use can also promote the development of chronic pain, illustrating 
the logical fallacy in treating chronic pain with prescription opioids. As with other 
addictive drugs, repeated opioid administration can shift the balance between 
reward and antireward processes, affecting the ability to experience positive emo-
tions from natural rewards over time [47]. This shift in balance is accompanied by 
amplification of the antireward state, effectively establishing a reward deficit state, 
which drives further opioid use to compensate [47, 50]. Allostatic changes from pain 
stimuli are amplified when opioids are misused [51–53], resulting in neural adapta-
tions that promote hyperalgesia, drug tolerance, and difficulty regulating emotion, 
which can in turn amplify anhedonia, producing a downward spiral of chronic pain 
and further prescription opioid misuse [53].
4. Shared psychosocial factors in addiction and chronic pain
As is evident from the sections above summarizing neural circuitry involved in 
addiction and chronic pain, the boundary between the neurobiological and psycho-
logical aspects of these conditions is somewhat arbitrary. Likewise, the boundary 
between the psychological and social components is poorly defined, reflecting 
the central concept of the BPS model, that health and disease involve biological, 
psychological, and social factors that influence one another in a reciprocal, highly 
dynamic manner [54]. Meints and Edwards (2018) divide psychosocial variables 
involved in chronic pain into two main categories. General psychosocial factors 
include affect, trauma, social/interpersonal disposition, sex- and race-related 
disparities, and pain-specific psychosocial factors include catastrophizing, coping, 
expectations, and self-efficacy [54]. Another way of conceptualizing the division is 
factors that predispose an individual to develop chronic pain and those that emerge 
as a consequence of pain. As discussed below, there is a high degree of overlap 
between the psychosocial aspects of chronic pain and addiction, and it is not always 
easy to make the distinction between cause and consequence in SUD.
Psychosocial factors influencing reward, stress, and motivation can contribute 
to a downward spiral of chronic pain and comorbid conditions [46]. It is well-
known that negative affect promotes drug use, while conversely, repeated drug use 
increases risk for depression and anxiety. Similarly, anhedonic depressive symp-
toms often exceed 50% comorbidity in individuals suffering from fibromyalgia, 
temporomandibular joint disorder, chronic spinal pain, and chronic abdominal 
pain [5]. Symptoms of depression and anxiety are prominent in both episodic and 
chronic cluster headaches, with those in the chronic subset being less likely to cog-
nitively reframe their pain sensations and more likely to ruminate [55]. In contrast 
to the bidirectional nature of negative affect and SUD, depression and anxiety are 
strong predictors of pain and related disability, but neither pain nor related disabil-
ity appear to be good predictors of depression and anxiety [54]. Affective factors 
are a strong predictors of opioid misuse, with mood disorders, anxiety disorders, 
and chronic pain conditions either preceding or overlapping with OUD [9, 56–60]. 
Furthermore, negative affect and cognitions increase risk of developing an OUD in 
surgical patients, as their pre-operative presence were major predictors of pro-
longed opioid cessation following the operation [61]. Childhood physical, psycho-
logical, and sexual abuse have been implicated in later-life development of several 
chronic pain conditions [54], as well as alcohol and drug abuse [62]. Post-traumatic 
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stress disorder (PTSD) in adult veterans (which can be related to combat exposure 
and/or injuries such as traumatic brain injury) and in victims of childhood abuse 
are highly associated with development of chronic pain [54] and substance use [63].
Deficits in executive function can contribute to and result from repeated drug 
use. Likewise, chronic pain is associated with impairments in memory, attention, 
and cognitive flexibility, although the relationship is a complex one, owing to a 
lack of standard tests and poor control of confounding variables such as sleep 
and medication in existing studies [64]. Working memory and emotional control 
were shown to be impaired in chronic pain patients, but neither the intensity nor 
the duration of pain itself predicted executive dysfunction [65]. As with negative 
affect, poor executive function may predispose the development of chronic pain, 
a notion supported by a recent study wherein poor cognitive performance before 
surgery on Trail-Making Test B and Rey-Osterrieth Complex Figure copy and recall 
predicted the persistence of pain up to 12 months after surgery [66]. Relatedly, 
while impulsivity is not generally prominent in chronic pain patients [67], this 
trait is quite pronounced in SUD [29] and may play a key role in determining the 
likelihood of opioid misuse in pain patients. Specifically, urgency and attentional 
impulsivity have been implicated in current and future misuse of opioids by chronic 
pain patients, while sensation-seeking seems to have little to no influence [67, 68]. 
High baseline impulsivity in rats was also correlated with high impulsivity in the 
variable delay-to-signal test after spared nerve injury [69]. Additionally, a recent 
study showed that decision-making in the Iowa Gambling Task by chronic pain 
patients was robustly modeled mathematically by over-valuation of gains and 
under-valuation of losses, typical of risk-taking [70]. Risky decision-making and 
lifestyle is also highly prevalent with long-term substance use [9], which may, in 
turn, increase risk for developing a chronic pain condition. For example, prescrip-
tion opioid use was associated with a 47% increased risk of car crash initiation, and 
thus, injury [6]. Other drug-associated behavior, such as injecting and high-risk or 
illegal activity to obtain drugs could also contribute to chronic pain and vice versa.
Much research underscores the importance of social support in ameliorating 
pain and improving function in chronic pain [12, 54], as well as preventing relapse 
in SUD [71]. However, negative social interactions can have the opposite effect. For 
example, the “sick role” of individuals experiencing chronic pain is a social context 
accompanied by attention, pity, and permitted exemption from daily routines [40]. 
Although moderately pleasurable for the individual experiencing pain, socio-
emotional pain relief is stressful for family and friends, and may promote aversion 
and distaste of the individual that has assumed it. This can cause isolation, com-
munication deficits, emotional setbacks, and may amplify the original chronic pain 
state without the presence of a nociceptive stimulus [72]. Similarly, psychosocial 
stressors such as aversion, isolation, and other emotional setbacks are also heavily 
apparent in addiction and other mood disorders [8, 10]. Relatedly, family members 
and peers attitudes and behaviors also influence individuals with chronic pain and 
SUD. Parental catastrophizing, spousal/partner depression or avoidant, anxious 
attachment styles, lack of social support at work, and negative interactions with 
co-workers and workmans compensation programs can all promote chronic pain 
and disability [54]. Similar interpersonal factors are at play with SUD [73], and 
they can be particularly important for adolescents, whose peers and parents exert 
heavy influences over substance use by affecting availability of drugs and the child’s 
perception of approval/disapproval of drug use [74]. Therapies targeting positive 
behavioral change in the social context may be essential in combating both chronic 
pain and SUD.
In addition to interpersonal factors, gender and race are other aspects of the 
social milieu that can have profound positive or negative effects on physical and 
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mental health. While there can clearly be biological influences in both cases, such 
as chromosomal and hormonal influences in gender, and genetic variability in race, 
it is worth considering the social features, which may be even more important in 
determining risk for mental health-related functioning (as appears to be the case 
for schizophrenia; [75]). Females have a higher prevalence of pain, decreased pain 
threshold, more severe, recurrent, and longer duration of pain compared to males, 
differences explained at least in part by social factors, such as gender roles and 
differences in coping strategies [54]. Compared to men, women also show greater 
propensity for addiction to many drugs, including opioids, but research seems to 
have focused primarily on potential biological explanations for such differences 
[76, 77]. The negative impacts of alcohol and drug use are greater on Black and 
Hispanic Americans, although consumption patterns between Blacks, Hispanics, 
and Whites do not explain this difference (at least in relation to alcohol; [78]). 
Data are lacking for many ethnic groups regarding chronic pain, but Blacks and 
Asian Americans report higher levels of pain and lower pain tolerance compared 
to Caucasians, differences which may stem from racism, socioeconomic strain, 
and ineffective pain coping strategies [54]. Other structural vulnerability factors 
such as poor access to health care are likely to contribute to the unequal impacts 
of SUD and chronic pain on minority groups [79]. Further research is needed to 
gain a better understanding of how complex social and structural factors shape 
risk for chronic pain and SUD. The field of epigenetics, which has begun to address 
the neurobiological effects of well-known social context-related risk factors for 
schizophrenia - early life adversity, growing up in an urban environment, minority 
group position, and cannabis use [75] - holds great promise in advancing science, 
therapeutics, and social change, and underscores the strengths of the biopsychoso-
cial perspective.
5. Non-pharmacological treatments for addiction and chronic pain
The focus of biomedical interventions to manage chronic pain is primarily 
pharmacological, using opioid analgesics or surgical procedures [80]. However, 
surgery inherently subjects patients to risks associated with the surgical procedures, 
including more pain [80]. Likewise, opioids do not show substantial evidence for 
beneficial long-term pain management [80–82] and as discussed above, may even 
exacerbate it. For example, in a study of 26,014 individuals experiencing chronic 
back pain, psychological distress (depression, anxiety, posttraumatic stress disor-
der, and SUD), unhealthy lifestyle (obesity and smoking), and health care utiliza-
tion increased incrementally with duration of opioid use [83]. As chronic pain and 
long-term opioid use may cross-sensitize across multiple biopsychosocial domains, 
it is essential to identify alternative treatment options.
A large body of clinical evidence suggests that treatments such as cognitive 
behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) 
alleviate symptoms of depression, anxiety, SUD, and chronic pain [84] and that 
the core mesocorticolimbic structures impacted by SUD and chronic pain can be 
effectively targeted by innovative therapies [85]. The CDC has also recommended 
treatments like exercise therapy and CBT to reduce pain and improve function 
in patients with chronic pain [86]. These alternative treatments aim to directly 
dismantle the negative biofeedback created by drug- or pain-induced maladaptive 
changes within reward and stress circuitry. Although more research is needed, 
the authors suggest that a more integrated approach for managing chronic pain 
and addiction should include clinical mental health therapeutic techniques, 
discussed below.
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5.1 Cognitive behavioral therapy (CBT)
The goal of cognitive behavioral therapy (CBT) is to educate the client in the 
realm of positive coping strategies utilizing cognitive, respondent, and behavioral 
techniques [87]. CBT is designed to manage individual patient characteristics 
through a collaborative reframing of negative prediction, selective abstraction, 
and depersonalization to help the patient assume responsibility for their cognitions 
and behaviors. Cognitive behavioral therapists highlight the direct link between 
negative emotional states, sedentary cognitions, and resulting behaviors and seek 
to alter them in a holistic fashion that allows patients to grow through therapeutic 
change. This patient-therapist collaboration shakes sedentary perspectives and 
faulty core beliefs surrounding their ailment and allows the patient to reframe their 
thoughts and learn from new experiences.
Many individuals with SUD present to treatment unwillingly and approxi-
mately 45–50% will continue to use one or more drugs while in treatment [88]. 
In one study, CBT-treated individuals with SUD showed a 31% rate of abstinence 
compared to 13% abstinence rate in controls [89]. Compared to other psychosocial 
treatments, such as insight-oriented therapies involving psychoeducation, CBT 
appears more durable [90]. In the context of OUD, studies have shown that CBT 
alone does not lead to consistent therapeutic outcomes in patients, although it does 
seem to enhance the effects of methadone maintenance treatments (MMT) [91–93]. 
Combined treatment outcomes include greater attendance and treatment adherence 
and an increase in abstinence as evidenced by urine toxicology [88, 94]. Although 
reductions in substance use are often modest, sleeper effects, the notion that posi-
tive responses to CBT will increase over time, have been historically documented 
[95]. Relatedly, compared to MMT-only groups, or MMT and another independent 
counseling strategy, CBT has been associated with latent positive effects on psycho-
social functioning. For example, employment consistency was shown to increase 
in parallel to daily functioning, and stress was shown to decrease with increased 
cognitive coping skills, reduced opioid use, and less depressive symptomology [91, 
92]. Contingency management utilized within the context of CBT has been found to 
increase the likelihood of abstinence, and therefore may further enhance effective-
ness of SUD treatment [89, 96]. A study in rats also supports the use of contingency 
management to enhance the relative value of nondrug reinforcers (in this case, 
delayed food reward) versus immediate opioid delivery, suggesting that people 
may similarly develop delay-discounting (a behavioral component of impulsivity) 
because of contingencies in their environment [97]. Combining pharmacological 
treatment with CBT to increase coping skills appears to be a promising strategy for 
SUD and its effectiveness may lie in addressing the individual’s biopsychosocial 
functioning rather than simply treating withdrawal symptoms.
Recent international guidelines prescribe psychological interventions, rather 
than strictly pharmacological interventions, for the treatment of chronic nocicep-
tive pain [98]. In chronic pain, CBT aims to help the patient channel their pain-
related negative affect pain into a new cognitive interpretation of their sensations 
to increase their quality of life. Evidence has shown that outcomes from CBT-based 
interventions for chronic pain are moderate and comparable in efficacy to those for 
SUD. While CBT does not have a direct impact on the disability causing chronic pain 
[99], it has positive effects on patients’ cognitions and appears to increase quality of 
life. For example, participants were 3X as likely to report no pain interference after 
CBT techniques to target and reframe negative cognitive patterns associated with 
the perceptions of pain [100]. Likewise, unrelenting chronic pain from terminal ill-
ness can increase desire for hastened death, but CBT-based activities like education, 
targeting of negative appraisal states, and relaxation association have been shown 
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to allow management and attenuation of pain [101]. Experimental, graded in vivo 
exposure therapy, a broad-spectrum CBT technique, has been shown to have some 
success in targeting the fear-avoidance model of chronic pain. Here, exposure to 
fearful movements gradually reduces classically conditioned fear/anxiety to reduce 
avoidance of these movements over the long-term [102]. Although more research 
is necessary, CBT appears promising as an adjunctive treatment in chronic pain. It 
may also be effective in augmenting treatment for patients with comorbid chronic 
pain and OUD by targeting patients’ ability to cope with pain- and stress-related 
opioid craving.
5.2 Mindfulness-based stress reduction (MBSR)
Mindfulness is a novel treatment strategy with roots in Eastern religions and 
philosophies that aims to enhance the experience and understanding of positive 
emotions and dismantle aberrant learning underlying pathological thoughts and 
behaviors. At the core of mindful therapeutic practice is acceptance that the stress-
ors that trigger drug use or exacerbate chronic pain cannot be eliminated from one’s 
life, but that their responses to those stressors can be modified. Relatedly, MBSR 
teaches a non-judgmental approach to affective, cognitive, and behavioral states; 
whether a particular stimulus is positive or aversive makes no difference. Invocation 
of the present moment is also key, allowing the patient to moderate their awareness 
and attention by attending to themselves in the here-and-now. The idea is that this 
systematic awareness of the present state coupled with a non-judgmental, accepting 
attitude ameliorates stress by weakening the negative emotional states attached to 
stressors, and thereby interrupting the cycle of addiction/chronic pain and elimi-
nating the need to self-medicate.
Mindfulness programs are particularly efficacious for SUD because they address 
aberrant learning related to distressing stimuli and promote an openness to experi-
ence that leads to a reduction in future distress from those stimuli [103], rather than 
promoting avoidance of stressors or triggers, which does not address the underlying 
pathology. Mindfulness strategies also lead to pro-adaptive changes in intrapersonal 
thought patterns and ingrained belief systems, such as cues and cravings [104], 
while momentary awareness enhances an individual’s ability to accept and cope 
with negative experiences, such as relapse and risky behavior [105]. This momen-
tary acceptance of unpleasant stimuli leads to neurobiological alterations related 
to new learning, and consequently protects against relapse [103]. MBSR has been 
found to alter neurostructural changes in the mesocorticolimbic system and reduce 
autonomic arousal, physiological correlates to individual perceptual shifts, value 
and priority clarification, increased self-awareness, urge and craving shifts, and the 
ability to “let go” [106]. This sensory- and perception-focused strategy system has 
also been found to positively impact hedonic processing in the context of chronic 
pain and opioid management that interferes with habit-forming behaviors associ-
ated with addiction [107].
MBSR and similar strategies that target aberrant learning have been shown 
to interrupt the progression of addiction to opioids [107]. Mindfulness trainings 
reduce the intense neural reactivity to drug-cues, reduce cravings, and uncouple 
negative affective states from the previously induced, self-medicated state [108]. 
Functional MRI studies have revealed that MBSR can enhance top-down limbic-
striatal connections by strengthening associations between the PFC and the 
parietal regions of the brain [109, 110], suppressing the influences of craving and 
autonomic responses, and enhancing cognitive control and flexibility related to 
attention [109]. Furthermore, by promoting gratitude for positive experiences 
and acceptance of negative physical and affective states, MBSR has been shown to 
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reduce craving, downregulate sympathetic arousal, and heighten natural reward 
[111], essentially breaking the cycle of addiction. Compared to typical treatments 
for OUD that focus patient attention on suppression of craving, which can actually 
increase self-medication and relapse, mindfulness strategies that focus the attention 
of the patient on acceptance of substance use uncouples opioid craving and opioid 
use to promote long-term relapse prevention [109, 112, 113].
Utilizing mindfulness in the context of treating chronic pain is new to Western 
society. Eastern practices, such as Zen Buddhism and Hatha yoga, have been applied 
to a plethora of physical ailments for centuries, but now these are combined with 
traditional psychotherapies such as CBT and acceptance and commitment therapy 
[114]. As in addiction treatment, a non-judgmental stance is vitally important to 
MBSR-based treatment of chronic pain. The patient focuses their attention on 
uncomfortable physical sensations with no attempt to alter them, instead develop-
ing compassion toward both positive and aversive bodily experiences [114, 115]. 
Neuroimaging studies support the notion that MBSR strategies have allowed 
patients to adopt a new perception of their chronic pain. The chronic pain experi-
ence involves the interplay of nociceptive cues, cognitive distortions, and negative 
emotional appraisal. Compared to controls, subjects receiving mindfulness instruc-
tion showed reduced activity in the right amygdala, parahippocampus, and insula, 
and increased activation in the dorsomedial and other PFC subregions during the 
presentation of unpleasant visual stimuli, consistent with attenuated emotional 
activation [116]. Mindfulness training has also been shown to reduce pain sever-
ity and uncouple pain from opioid use by helping the patient attenuate negative 
appraisals, reduce fixation and hypervigilance from chronic pain, and reduce pain 
catastrophizing [86, 107, 117–120]. As in SUD, MBSR interventions help to disen-
gage the cycle of maladaptive pain coping strategies and prevent related behaviors, 
such as opiate stockpiling and other habits [107]. Together, these lines of evidence 
suggest that mindfulness-based therapeutic interventions hold great promise for 
treating and preventing OUDs, chronic pain, and co-expression of both, and the 
authors hypothesize that the biopsychosocial nature of the approach is key to its 
effectiveness.
5.3 Solution-focused brief psychotherapy (SFBP)
Solution-focused brief psychotherapy (SFBP) applies a postmodern construc-
tivist approach to counseling, meaning that an individual’s experience of their 
substance use acts as the “objective truth” [121]. In this way, the therapist will col-
laborate with the client in order to develop a working, clinical understanding of the 
client’s problem situation in terms of experience, perception, and meaning related 
to ambiguous stimuli and events [122]. Like CBT and MBSR, SFBP hinges on the 
development of a personalized construction of the problem behaviors or experi-
ences and reframing of meaning that perpetuates maladaptive cycles of thought 
and behavior. Some researchers believe that it is not the specific interventions, but 
the demeanor and actions of the therapist that promote the therapeutic effects of 
solution-focused therapy. The collaborative relationship extended by the therapist, 
use of core facilitative conditions of the counseling process, mindfulness of the 
stages of change, and a focus on solutions instead of problems provides moderate 
empirical backing [123–125]. SFBP practitioners believe that therapy relies on the 
therapist’s ability to engage the client in examining their negative status quo and that 
they become aware of exceptions to problem situations so as to direct insight toward 
future change [126]. SFBP allows the client to determine their own goals related to 
recovery, which includes harm-reduction strategies, and does not rely upon all-or-
nothing measures such as complete abstinence from drugs.
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Many reports support the notion that solution-focused brief psychotherapy 
(SFBP) has worked well for individuals with SUD, and more modern group-based 
SFBP approaches have continued to be successful [121, 122, 127]. Although research 
has stagnated somewhat, SFBP group therapy appears to be effective for treating 
SUD, sometimes outperforming traditional programs [127]. This success may lie in 
allowing patients to choose their own goal structures and giving them more respon-
sibility, which generally increases the likelihood of a positive therapeutic alliance 
between clinician and patient and typically yields better treatment outcomes [127]. 
Because depression and anxiety, like chronic pain, are highly comorbid with SUD, 
clinicians have had more success in targeting these disorders in order to address 
the other habitual drug-seeking behaviors [122, 127] and solution-focused tech-
niques have been found to outperform traditional therapies in this regard [127]. 
Specifically, interpersonal functioning, symptom severity, and social roles pre- and 
post- treatment, have shown improvements in those receiving solution-focused 
interventions [127–129]. Meta-analyses have also shown that 23% of systematic 
reviews have reported positive trends in depression-related outcomes [130, 131]. 
Applying a solution-focused mindset to other psychotherapies, including CBT and 
MBSR, has also led to positive outcomes in the treatment of SUD and depression 
[127, 132]. Another advantage of SFBP is its cost effectiveness, due to its brief dura-
tion yet surprisingly long-term positive outcomes for many. Although no studies 
to date have examined the efficacy of SFBP specifically for the treatment of OUD, 
application of this approach to OUD seems promising.
In the context of chronic pain, the emphasis of solution-searching in SFBP may 
be advantageous, as individuals living with chronic pain typically react passively to 
their pain sensations, or develop coping strategies that can be misguided or unhelp-
ful [133]. The idea of a “preferred future,” a concept at the core of SFBP wherein the 
therapist assists the patient in identifying exceptions to their painful status quo, has 
elicited unique responses from patients often lacking in hope [126, 133]. Research 
on the therapeutic effects of SFBP for chronic pain is quite limited. However, SFBP 
has been helpful when coupled with physical rehabilitative practices. Two studies 
have shown improvement of individuals undergoing orthopedic rehabilitation 
while on sick leave, with over 60% of participants returning to homeostatic daily 
functioning levels as a result of solution-focused practices, as opposed to a 13% 
return rate from the waitlisted control groups [134, 135]. A case study also supports 
the efficacy of combined biofeedback (galvanic skin response) and SFBP in order 
to manage chronic pain associated with gastro-esophageal reflux disease, with the 
patient showing a significant decrease in chest pain and increase in personal life 
satisfaction lasting two months post-treatment [136]. Further research on biopsy-
chological interventions such as combining biofeedback with SFBP for chronic pain 
could be illuminating.
5.4 Motivational interviewing (MI)
Originally developed by Dr. William Miller for alcohol use disorders in 1983, 
motivational interviewing (MI) can be described as a therapeutic conversation, 
held by the therapist and client, about aspects of change [137]. Therapists use spe-
cific communication strategies that allow the client to explore their arguments for 
why change is not possible, seeking to elicit “change talk” from the client by devel-
oping discrepancies in the way the client thinks and speaks about their issues. These 
discrepancies arise from a collaborative exploration of the client’s story pertaining 
to how substance use, for example, has impacted their lives. The therapist’s role is 
to highlight ambivalence that has arisen from the storytelling and provide space for 
the client to think about what changes they are capable of making [138]. Eventually, 
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by weighing personalized positive and negative aspects related to change outcomes, 
the client breaks down the lines of logic sustaining pathological behaviors  
[139, 140]. MI addresses four processes: engaging, focusing, evoking, and planning 
[141]. Engaging the client in a person-centered style develops the therapeutic 
bond that will facilitate change [141]. Focus revolves around the change target of 
the client, which is developed collaboratively to avoid negative power dynamics, 
polarization, or fractures to the therapeutic relationship [142]. Evocation involves 
intentional change talk wherein the client must identify their own personal reasons 
for change and therapist feedback aims to prevent potential losses in motivation 
related to these reasons. Planning involves collaboration and commitment as the 
primary method for enforcing the desired change. The ability for the client to elicit 
their own motivations for change rather than the therapist imposing their own 
advice is the driving force of this therapy.
MI has become one of the leading theoretical interventions for treating indi-
viduals with SUD. Some early explanations of its popularity are its cost effective-
ness, theoretical fluidity, usefulness for non-treatment-seeking populations, and 
motivational enhancement of the client, which is highly important in addiction 
treatment [143, 144]. Although there have only been a handful of studies, MI 
has shown clinical efficacy in the treatment of a variety of SUD [143, 145]. For 
example, the ability to resolve ambivalence related to drug use and to reframe 
one’s perspective of change ultimately reduced active drug use to a larger extent 
in an MI group compared to a more confrontational counseling style focused on 
the consequences of risky drug use [138, 139, 146]. Change talk has been shown to 
play a vital role in treatment outcomes and researchers have hypothesized that it 
promotes a neurocognitive shift negatively correlated with substance use [147, 148]. 
For example, an fMRI study showed that positive change talk inhibited activation of 
reward circuitry by alcohol-associated cues, suggesting that change talk can nullify 
reward activation under high-risk circumstances and thereby prevent cue-induced 
relapse [147, 149]. A single-blinded, randomly controlled trial found that bimonthly 
MI treatment significantly reduced the number of opioid overdose events and 
promoted a lower attrition rate amongst participants [150] compared to psycho-
education and tertiary prevention strategies [150, 151]. Educational programs did 
reduce other risk factors, such as viral infections as a result of needle misuse and 
enhanced protective factors including how to detect overdose, promotion of needle 
exchanges, and safe injection habits [151]. Future studies examining potential 
benefits of combined pharmacological and MI methods on treatment outcomes for 
patients with OUD will be important.
Although controlled studies have been limited by the fluidity of motivational 
strategies and their implementation, researchers have found that MI can aug-
ment treatment of chronic pain, and is moderately effective for lower-back pain, 
asthma, hypertension, cardiac and respiratory issues, and fibromyalgia [152]. In 
this context, the focus of MI is on resolving ambivalence through change talk and 
enhancing the ability to cope with chronic pain by incorporating mindfulness and 
cognitive restructuring techniques [153–155]. In addition, MI interventions used in 
conjunction with physiotherapy enhance the therapeutic relationship between the 
physician and patient, which correlates to more positive outcome expectancies of 
the patient that ultimately decrease subjective pain intensity and increase range in 
physical functioning [156]. Another study found that infusing a biopsychosocial 
assessment of chronic pain with MI also had more favorable outcomes, including 
marital satisfaction, reductions in pain intensity, stability in positive mood, lower 
ratings of personal distress, and higher ratings of empathy [155]. Future studies 
examining the efficacy of MI in treating comorbid SUD and chronic pain would be 
informative.
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6. Conclusions
Chronic pain and addiction are widespread, pervasive, and significant public 
health burdens that demonstrate a need for more effective management strategies. 
The known effectiveness of opioids for managing acute pain combined with the 
limited therapeutic alternatives for chronic pain, have led to an overreliance on 
opioids for long-term pain management and the current opioid crisis in the United 
States [2]. In this chapter, the authors have discussed conceptualizing chronic 
pain and SUD using a similar biopsychosocial framework and suggest that both 
can be more effectively managed by including clinical mental health therapeutic 
techniques as opposed to a purely biomedical approach. While psychotherapy 
has long been used in treating SUD, applying these techniques to chronic pain is 
fairly novel. Evidence of the effectiveness of these nonpharmacological treatments 
for chronic pain, particularly for long-term management, is still sparse [157]. 
However, the techniques highlighted in this review, CBT, MBSR, SFBP, and MI are 
promising in managing mental illnesses that are frequently comorbid with chronic 
pain, suggesting further research into their efficacy for chronic pain is warranted. 
Moreover, the biopsychosocial parallels between chronic pain and SUD represent 
potential areas of translational research to further improve these nonpharmaco-
logical pain management practices and foment social change. By addressing these 
areas of biopsychosocial overlap, nonpharmacological approaches may hold great 
promise in reducing the negative impacts of chronic pain and the opioid epidemic 
simultaneously.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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